Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan Extension Study in Participants With ADPKD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Participants who had successfully completed a Phase 1, 2, or 3 tolvaptan ADPKD or renal impairment study, with a confirmed diagnosis of ADPKD from prior studies \[either 156-04-251 (NCT00428948) or 156-04-250 (NCT00413777), 156-06-260, 156-09-284 (NCT01336972), 156-09-285 (NCT01210560), and 156-09-290 (NCT01451827)\].~Exclusion Criteria:~* Participants unable to provide written informed consent.~* Participants (men or women) would not adhere to the reproductive precautions as outlined in the Informed Consent Form.~* Participants (women only) with a positive urine pregnancy test.~* Participants who were pregnant or breast-feeding.~* Participants unable to take oral medications.~* Participants who had allergic reactions to tolvaptan or chemically related structures such as benzazepines (benzazepril, conivaptan, fenoldopam mesylate, or mirtazapine).~* Participants with disorders in thirst recognition or an inability to access fluids.~* Participants with critical electrolyte imbalances, as determined by the investigator~* Participants with or at risk of significant hypovolemia, as determined by investigator.~* Participants with significant anemia, as determined by investigator.~* Participants with a history of substance abuse (within the last 3 years).~* Participants who were taking other experimental (that is, non-marketed) therapies or were participating in another clinical drug or device study; participating in the off-drug follow-up period of another ADPKD trial with tolvaptan was permitted.~* Participants unable to complete magnetic resonance imaging (MRI) assessments (for example, participants with ferro-magnetic prostheses, aneurysm clips, severe claustrophobia).~* Participants who had taken a vasopressin antagonist (outside of previous participation in a tolvaptan study).~* Participants unable to comply with anti-hypertensive or other important medical therapy.~* Participants with advanced diabetes.~* Participants who were taking medications or had an illness that could confound endpoint assessments (including taking approved therapies for the purpose of affecting polycystic kidney disease \[PKD\] cysts).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 milligrams (mg) in the morning \[AM\]/15 mg in the evening \[PM\] titrated to 60 mg \[AM\]/30 mg \[PM\], then 90 mg \[AM\]/30 mg \[PM\] based on tolerability were given orally twice daily until the last participant originating from prior studies (either 156-04-251 or 156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290) who was eligible for efficacy analysis completed the Month 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).